Falck is the UK’s leading provider of Patient Transport. Operating from 7 regional headquarters nationwide, we offer a range of patient transport services including non-emergency, high dependency, renal, bariatric, urgent care and paediatric retrieval as well as A&E and front line response through our Emergency Ambulance Division. Falck in the UK is a subsidiary of the Falck Group, the global leader in emergency and ambulance services. Present across 44 countries on six continents and operating more than 2500 ambulances, Falck has the world’s largest international ambulance fleet.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

news image

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme | August 20, 2020

news image

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

news image

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More

INDUSTRIAL IMPACT

AMNIO TECHNOLOGY LAUNCHES TWO NEW DUAL-LAYER ALLOGRAFTS, FDA RECOGNIZES PRODUCTS AS MINIMALLY MANIPULATED, HOMOLOGOUS USE HCT/PS

Amnio Technology | February 15, 2022

news image

Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial ...

Read More
news image

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More
news image

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme | August 20, 2020

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More
news image

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More
news image

INDUSTRIAL IMPACT

AMNIO TECHNOLOGY LAUNCHES TWO NEW DUAL-LAYER ALLOGRAFTS, FDA RECOGNIZES PRODUCTS AS MINIMALLY MANIPULATED, HOMOLOGOUS USE HCT/PS

Amnio Technology | February 15, 2022

Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial ...

Read More